Zsuzsanna Devecseri, MD of @SanofiGenzyme @sanofi discusses the pivotal Phase 3 ICARIA-MM trial of isatuximab, an investigational anti-CD38 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM) presented at the ASH.
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
